Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach

Immunogenomics were used to identify tumor-specific neoantigens in two well characterized models of glioblastoma. Endogenous immune responses harbored neoantigen-specific T cells within the brain and lymph nodes, providing a tractable system for additional preclinical immunotherapeutic studies in these systems. The “cancer immunogenomics” paradigm has facilitated the search for tumor-specific antigens over the last 4 years by applying comprehensive cancer genomics to tumor antigen discovery. We applied this methodology to identify tumor-specific “neoantigens” in the C57BL/6-derived GL261 and VM/Dk-derived SMA-560 tumor models. Following DNA whole-exome and RNA sequencing, high-affinity candidate neoepitopes were predicted and screened for immunogenicity by ELISPOT and tetramer analyses. GL261 and SMA-560 harbored 4,932 and 2,171 nonsynonymous exome mutations, respectively, of which less than half were expressed. To establish the immunogenicities of H-2Kb and H-2Db candidate neoantigens, we assessed the ability of the epitopes predicted in silico to be the highest affinity binders to activate tumor-infiltrating T cells harvested from GL261 and SMA-560 tumors. Using IFNγ ELISPOT, we confirmed H-2Db–restricted Imp3D81N (GL261) and Odc1Q129L (SMA-560) along with H-2Kb–restricted E2f8K272R (SMA-560) as endogenous tumor-specific neoantigens that are functionally immunogenic. Furthermore, neoantigen-specific T cells to Imp3D81N and Odc1Q129L were detected within intracranial tumors as well as cervical draining lymph nodes by tetramer analysis. By establishing the immunogenicities of predicted high-affinity neoepitopes in these models, we extend the immunogenomics-based neoantigen discovery pipeline to glioblastoma models and provide a tractable system to further study the mechanism of action of T cell–activating immunotherapeutic approaches in preclinical models of glioblastoma. Cancer Immunol Res; 4(12); 1007–15. ©2016 AACR.

[1]  J. Wolchok,et al.  Targeting T Cell Co-receptors for Cancer Therapy. , 2016, Immunity.

[2]  H. Goel,et al.  IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG , 2016, Oncogene.

[3]  Kristen L. Jones,et al.  Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model , 2015, Cancer Immunology Research.

[4]  G. Dunn,et al.  Principles of immunology and its nuances in the central nervous system. , 2015, Neuro-oncology.

[5]  In-Hee Lee,et al.  Spatiotemporal Evolution of the Primary Glioblastoma Genome. , 2015, Cancer cell.

[6]  Maxim N. Artyomov,et al.  Tumor neoantigens: building a framework for personalized cancer immunotherapy. , 2015, The Journal of clinical investigation.

[7]  Michael Detmar,et al.  A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules , 2015 .

[8]  M. Clerici.  Faculty Opinions recommendation of Structural and functional features of central nervous system lymphatic vessels. , 2015 .

[9]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L. Liau,et al.  Dendritic cell immunotherapy for brain tumors , 2015, Journal of Neuro-Oncology.

[11]  E. Mardis,et al.  A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells , 2015, Science.

[12]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[13]  Susan M. Chang,et al.  Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment , 2015, Acta Neuropathologica.

[14]  Z. Modrušan,et al.  Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing , 2014, Nature.

[15]  Maxim N. Artyomov,et al.  Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens , 2014, Nature.

[16]  Christopher M. Jackson,et al.  Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model , 2014, PloS one.

[17]  S. Rosenberg,et al.  Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.

[18]  Y. Cheng,et al.  Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors , 2014, Clinical Cancer Research.

[19]  Susan M. Chang,et al.  Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. , 2014, Neuro-oncology.

[20]  P. Coulie,et al.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy , 2014, Nature Reviews Cancer.

[21]  Steven J. M. Jones,et al.  Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.

[22]  M. Stratton,et al.  Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[24]  John Wong,et al.  Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. , 2013, International journal of radiation oncology, biology, physics.

[25]  Jimmy Lin,et al.  Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.

[26]  N. Hacohen,et al.  Cancer Immunology at the Crossroads : Functional Genomics Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines , 2013 .

[27]  W. Curry,et al.  Cancer immunoediting in malignant glioma. , 2012, Neurosurgery.

[28]  S. Phuphanich,et al.  Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma , 2012, Cancer Immunology, Immunotherapy.

[29]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[30]  Lynda Chin,et al.  Emerging insights into the molecular and cellular basis of glioblastoma. , 2012, Genes & development.

[31]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[32]  J. Castle,et al.  Exploiting the mutanome for tumor vaccination. , 2012, Cancer research.

[33]  E. Mardis,et al.  Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.

[34]  Ken Chen,et al.  SomaticSniper: identification of somatic point mutations in whole genome sequencing data , 2012, Bioinform..

[35]  Hiroshi Mamitsuka,et al.  Toward more accurate pan-specific MHC-peptide binding prediction: a review of current methods and tools , 2011, Briefings Bioinform..

[36]  Hiroshi Mamitsuka,et al.  Towardmore accurate pan-specific MHC-peptide binding prediction : a review of current methods and tools , 2012 .

[37]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[38]  Philip C. De Witt Hamer,et al.  Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies , 2010 .

[39]  P. C. de Witt Hamer.  Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. , 2010, Neuro-oncology.

[40]  A. Friedman,et al.  An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme , 2009, Molecular Cancer Therapeutics.

[41]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[42]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[43]  W. London,et al.  ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. , 2008, Cancer research.

[44]  T. Schumacher,et al.  Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7 , 2008, Proceedings of the National Academy of Sciences.

[45]  K. Kinzler,et al.  Epitope landscape in breast and colorectal cancer. , 2008, Cancer research.

[46]  V. Brusic,et al.  Evaluation of MHC class I peptide binding prediction servers: Applications for vaccine research , 2008, BMC Immunology.

[47]  Morten Nielsen,et al.  Modeling the adaptive immune system: predictions and simulations , 2007, Bioinform..

[48]  Rebecca A Betensky,et al.  Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. , 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  D. Bigner,et al.  Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function , 2007, Clinical Cancer Research.

[50]  Tracy T Batchelor,et al.  A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. , 2006, Cancer research.

[51]  T. Kawase,et al.  Identification of a glioma antigen, GARC‐1, using cytotoxic T lymphocytes induced by HSV cancer vaccine , 2006, International journal of cancer.

[52]  T. Schumacher,et al.  Design and use of conditional MHC class I ligands , 2006, Nature Medicine.

[53]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[54]  P. Knopf,et al.  Drainage of Brain Extracellular Fluid into Blood and Deep Cervical Lymph and its Immunological Significance , 1992, Brain pathology.

[55]  H. Fraser.  Astrocytomas in an inbred mouse strain , 1971, The Journal of pathology.

[56]  D. Rall,et al.  Studies on the chemotherapy of experimental brain tumors: development of an experimental model. , 1970, Cancer research.